TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Autor:	Erzsébet Juhász, Thaddeus Beck, Jean-Marc Limacher, Helen J. Ross, Anton Melnyk, Zsuzsanna Mark, Rosa Alvarez, Joseph Potz, Arnaud Scherpereel, Lecia V. Sequist, Jean-Philippe Oster, Elisabeth Quoix, Nandagopal Vrindavanam, John Nemunaitis, Piotr Jaskiewicz, Saiama N. Waqar
Jazyk:	angličtina
Rok vydání:	2014
Předmět:	Cancer Research medicine.medical_treatment Immunology non-small cell lung cancer (NSCLC) chemical and pharmacologic phenomena CD16 Bioinformatics complex mixtures First line therapy Text mining Antigen Immunology and Allergy Medicine MUC1 Pharmacology business.industry CD69 hemic and immune systems Immunotherapy medicine.disease biological factors Oncology Cancer research Molecular Medicine Oral Presentation business
Zdroj:	Journal for Immunotherapy of Cancer
ISSN:	2051-1426
Popis:	Meeting abstracts TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor-associated antigen and interleukin-2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker for TG4010 efficacy
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b44054eb9b4d7a1e3a215ce3a1786bc http://europepmc.org/articles/PMC4288318 Zobrazit plný text záznamu Full text from SpringerLink